Morgan Stanley keeps BioMarin at Overweight but cuts price target to $103
Morgan Stanley kept its Overweight rating on BioMarin Pharmaceutical and lowered the price target from $119 to $103. Source: TradingView, data from Benzinga.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley analysts kept their Overweight rating on BioMarin Pharmaceutical shares but reduced the price target from $119 to $103, a cut of 13.4%. According to the bank, the stock closed at $56.70 on November 12, and the new target implies an upside of 81.7%.
According to TradingView, citing Benzinga, price targets across the five most recent analyst notes over the past 30 days range from $60 to $119. Recent notes came from JP Morgan ($86), Oppenheimer ($94), HC Wainwright and RBC Capital ($60).
why it matters
Rating updates like this are routine for the market and usually affect only one stock. A lower target alongside a positive rating suggests a more cautious view of the company, but it does not change the broader picture for the biotechnology sector.
tags
instruments
sources
- Morgan Stanley maintains BioMarin Pharmaceutical at Overweight, lowers price target to $103 from $119 — TradingView, 13 November 2026 at 17:46 UTC
- Morgan Stanley maintains Denali Therapeutics at Overweight, lowers price target to $37 from $42 — TradingView, 13 November 2026 at 17:48 UTC
- Morgan Stanley maintains argenx at Overweight, lowers price target to $1130 from $1190 — TradingView, 13 November 2026 at 17:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗